Physician profile
Ronald Wayne Bruce
NPI 1922145168
$923.53
in general payments reported to CMS, 2019-2025
15 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $58.97 · 2021: $84.59 · 2022: $54.34 · 2023: $157 · 2024: $165 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437 · Education: $17.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $437.21 |
| Education | $17.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $139.77 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $124.67 | 2019-2023 | Xarelto |
| Merz North America, INC. | $108.76 | 2024 | |
| Lilly USA, LLC | $107.67 | 2020-2023 | Mounjaro |
| Novo Nordisk INC | $88.66 | 2024-2025 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.58 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $65.22 | 2019-2022 | |
| Pfizer INC. | $62.45 | 2019-2020 | |
| Dexcom, INC. | $33.31 | 2023-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $31.61 | 2023 | Trelegy Ellipta, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $15.61 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.11 | 2021 | |
| Esperion Therapeutics, INC. | $14.83 | 2021 | |
| Amgen INC. | $13.89 | 2020 | |
| Abbott Laboratories | $13.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Bruce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.